Recent updates in the management of chemotherapy induced nausea and vomiting
Publication Type:Journal Article
Source:Asian Journal of Pharmaceutical and Clinical Research, Volume 6, Number SUPPL.4, p.5-10 (2013)
Keywords:akathisia, alprazolam, antiemetic activity, antineoplastic agent, aprepitant, apretero, benzodiazepine derivative, cannabinoid, carmustine, chemotherapy induced nausea and vomiting, chlorpromazine, cisplatin, confusion, constipation, corticosteroid, dexamethasone, diarrhea, dizziness, dolasetron mesilate, domperidone, dopamine receptor blocking agent, dronabinol, drowsiness, drug absorption, drug efficacy, drug half life, drug penetration, drug potentiation, drug preference, dysphoria, dystonia, fatigue, fosaprepitant, granisetron, haloperidol, headache, human, hyperglycemia, indigestion, insomnia, lorazepam, methylprednisolone, metoclopramide, midazolam, nabilone, neurokinin 1 receptor antagonist, olanzapine, ondansetron, palonosetron, pathophysiology, practice guideline, prochlorperazine, recommended drug dose, repeated drug dose, review, risk factor, sedation, serotonin 3 antagonist, side effect, tropisetron, unclassified drug, unindexed drug, visual disorder, xerostomia
The leading factor that has an impact on cancer patients' quality of life and their adherence to treatment is chemotherapy induced nausea and vomiting (CINV). Better understanding of the physiology of CINV and the identification of risk factors can be beneficial in improving the treatment outcomes. A number of antiemetic agents are currently available including 5-hydroxytryptamine receptor antagonists (5HT3RAs), neurokinin receptor antagonists (NK1RAs), dopamine receptor antagonists, benzodiazepines and cannabinoids. These agents can be used in the effective management of CINV according to the various antiemetic guidelines like NCCN (National Comprehensive Cancer Network) guidelines, ASCO (American Society of Clinical Oncology) guidelines and MASCC (Multinational Association of Supportive Care in Cancer) guidelines. Even though CINV can be prevented to a great extent with these agents, some patients still experience nausea and vomiting. In order to attain the ultimate goal of complete control of CINV, more effective therapies are greatly needed. This review focuses on the pathophysiological aspects of CINV, antiemetic agents, current guidelines for management of CINV, their comparative evaluation and recent trends in management of CINV.
cited By (since 1996)0
Cite this Research Publication
Related Research Publications
- Incretin analogue, liraglutide a newer treatment approach for type-2 diabetes mellitus
- Effect of pre-operative discontinuation of angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists on intra-operative arterial pressures after induction of general anesthesia
- Sequential release of epigallocatechin gallate and paclitaxel from PLGA-casein core/shell nanoparticles sensitizes drug-resistant breast cancer cells
- Thermo-responsive fibrinogen nanogels: a viable thermo-responsive drug delivery agent for breast cancer therapy?
- Structure-function prediction of α2A-, α2B-, and α2C-adrenoceptors using homology model assisted antagonist binding study